1219694-10-6

Basic information

• Product Name: C₂₅H₂₄O₇
• Synonyms: C₂₅H₂₄O₇
• CAS NO: 1219694-10-6
• Molecular Weight: 436.461
• Mol File: 1219694-10-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: C₂₅H₂₄O₇(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₅H₂₄O₇(1219694-10-6)
• EPA Substance Registry System: C₂₅H₂₄O₇(1219694-10-6)

Safety Data

• Hazardous Substances Data: 1219694-10-6(Hazardous Substances Data)

Upstream product

• 120-57-0 piperonal 
• 4405-18-9 5-[1,3]dioxolan-2-yl-benzo[1,3]dioxole 
• 6346-05-0 3-benzyloxy-4-methoxybenzaldehyde 

Downstream Products

• 1219693-97-6 10-(3-benzyloxy-4-methoxy-phenyl)-furo[3',4':6,7]naphtho[1,2-d][1,3]dioxole-7,9-dione 
• 1219694-03-7 10-(3-benzyloxy-4-methoxy-phenyl)-7H-furo[3',4':6,7]naphtho[1,2-d][1,3]dioxol-9-one 
• 1219694-04-8 10-(3-hydroxy-4-methoxy-phenyl)-9H-furo[3',4':6,7]naphtho[1,2-d][1,3]dioxol-7-one 
• 1219694-02-6 10-(3-benzyloxy-4-methoxy-phenyl)-9H-furo[3',4':6,7]naphtho[1,2-d][1,3]dioxol-7-one 
• 1428438-79-2 C₃₈H₄₈O₉ 
• 1428438-78-1 C₃₂H₃₈O₈ 
• 1428438-77-0 C₂₆H₂₈O₇ 
• 1428438-76-9 C₂₆H₂₄O₉ 
• 1428438-75-8 C₂₂H₂₀O₇ 
• 1428438-74-7 C₂₀H₁₈O₆ 
• 1428438-60-1 C₂₀H₁₄O₆ 
• 1428438-59-8 C₂₂H₁₆O₇ 

Relevant articles and documents

Synthesis and biological evaluation of helioxanthin analogues

Helioxanthin and analogues have been demonstrated to suppress gene expression of human hepatitis B virus. In the continuous attempt to optimize antiviral activity, various structural motifs were grafted on the helioxanthin scaffold. Many such analogues were synthesized and evaluated for their anti-hepatitis B virus activity. Structure-activity relationships of these helioxanthin derivatives are also discussed. Among these new compounds, 15 exhibits the highest activity against HBV (EC50 = 0.06 μM). This compound can suppress viral surface antigen and DNA expression. Furthermore, viral RNA is also diminished while the core promoter is deactivated upon treatment by 15. A plausible working mechanism is postulated. Our results establish helioxanthin lignans as potent anti-HBV agents with unique mode of action. Since their antiviral mechanism is distinct from current nucleoside/nucleotide drugs, helioxanthin lignans constitute a potentially new class of anti-HBV agents for combination therapy.